Search Results - Charles G Drake

  • Showing 1 - 15 results of 15
Refine Results
  1. 1

    Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data. by Takeshi Azuma, Gefeng Zhu, Haiying Xu, A Cecilia Rietz, Charles G Drake, Eric L Matteson, Lieping Chen

    Published in PLoS Medicine (2009-10-01)
    Get full text
    Article


  2. 2

    A phased strategy to differentiate human CD14+monocytes into classically and alternatively activated macrophages and dendritic cells by Jelani C. Zarif, James R. Hernandez, James E. Verdone, Scott P. Campbell, Charles G. Drake, Kenneth J. Pienta

    Published in BioTechniques (2016-07-01)
    Get full text
    Article


  3. 3

    329 Longitudinal immune profiling reveals unique myeloid and T cell phenotypes associated with spontaneous immunoediting in a novel prostate tumor model by Casey Ager, Aleksandar Obradovic, Juan M. Arriaga, Matthew G. Chaimowitz, Cory Abate-Shen, Andrea Califano, Charles G. Drake

    Get full text
    Article


  4. 4

    Systemic depletion of lymphocytes following focal radiation to the brain in a murine model by Anna F. Piotrowski, Thomas R. Nirschl, Esteban Velarde, Lee Blosser, Sudipto Ganguly, Kathleen H. Burns, Leo Luznik, John Wong, Charles G. Drake, Stuart A. Grossman

    Published in OncoImmunology (2018-07-01)
    Get full text
    Article


  5. 5

    KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response by Charles G Drake, Benjamin Izar, Casey R Ager, Aleksandar Obradovic, Matthew Chaimowitz, Catherine Spina, Mingxuan Zhang, Shruti Bansal, Somnath Tagore, Collin Jugler, Meri Rogava, Johannes C Melms, Patrick McCann, Matthew C Dallos

    Published in Journal for ImmunoTherapy of Cancer (2023-09-01)
    Get full text
    Article


  6. 6

    A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone by Yiyi Chen, Charles G Drake, William L Redmond, Yoshinobu Koguchi, Tomasz M Beer, Julie N Graff, Joshi J Alumkal, Rachel E Slottke, George V Thomas, Reid F Thompson, Mary A Wood, Emile Latour, Raymond C Bergan, Amy E Moran

    Published in Journal for ImmunoTherapy of Cancer (2020-10-01)
    Get full text
    Article


  7. 7

    High-dimensional mapping of human CEACAM1 expression on immune cells and association with melanoma drug resistance by Yu-Hwa Huang, Charles H. Yoon, Amit Gandhi, Thomas Hanley, Carlos Castrillon, Yasuyuki Kondo, Xi Lin, Walter Kim, Chao Yang, Amine Driouchi, Michael Carroll, Scott D. Gray-Owen, Duane R. Wesemann, Charles G. Drake, Monica M. Bertagnolli, Nicole Beauchemin, Richard S. Blumberg

    Published in Communications Medicine (2024-07-01)
    Get full text
    Article


  8. 8

    Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer by Hannah E. Bergom, Laura A. Sena, Abderrahman Day, Benjamin Miller, Carly D. Miller, John R. Lozada, Nicholas Zorko, Jinhua Wang, Eugene Shenderov, Francisco Pereira Lobo, Fernanda Caramella-Pereira, Luigi Marchionni, Charles G. Drake, Tamara Lotan, Angelo M. De Marzo, Justin Hwang, Emmanuel S. Antonarakis

    Published in npj Genomic Medicine (2024-01-01)
    Get full text
    Article


  9. 9

    TGM4: an immunogenic prostate-restricted antigen by Laura Crowley, Charles G Drake, Ran Reshef, Pawel Muranski, Aleksandar Obradovic, Timothy O’Donnell, Uri Laserson, Tiezheng Yuan, Emmanuel S Antonarakis, Zoila A Lopez-Bujanda, Thomas R Nirschl, Rodney Macedo, Alexandros Papachristodoulou, Jelani C Zarif, Mithil K Soni, Michael C Haffner, H Benjamin Larman, Michael M Shen

    Published in Journal for ImmunoTherapy of Cancer (2021-06-01)
    Get full text
    Article


  10. 10

    The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma by Daniel P. Petrylak, Lawrence Fong, Charles G. Drake, Mark N. Stein, Douglas G. McNeel, Ravi A. Madan, James L. Gulley, Neil H. Bander, Tomasz M. Beer, Stacey Harrelson, Philip W. Kantoff, William K. Oh, David J. Peace, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Johannes Vieweg

    Published in Journal for ImmunoTherapy of Cancer (2016-12-01)
    Get full text
    Article


  11. 11

    Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma by Christina Jackson, Ada Tam, Sarah Harris-Bookman, Brian Francica, Charles G. Drake, Drew M. Pardoll, Debebe Theodros, Esteban Velarde, Betty Tyler, Xiaobu Ye, Henry Brem, Mark Selby, Dimitrios Mathios, Mira A. Patel, Jennifer E. Kim, Christina M. Kochel, Thomas R. Nirschl, Ali Ghasemzadeh, Christopher C. Jackson, Phuoc T. Tran, Vladimir Coric, Michael Lim

    Published in Journal for ImmunoTherapy of Cancer (2016-06-01)
    Get full text
    Article


  12. 12

    Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma by Christina Jackson, Ada Tam, Sarah Harris-Bookman, Brian Francica, Charles G. Drake, Drew M. Pardoll, Debebe Theodros, Esteban Velarde, Betty Tyler, Xiaobu Ye, Henry Brem, Mark Selby, Dimitrios Mathios, Mira A. Patel, Jennifer E. Kim, Christina M. Kochel, Thomas R. Nirschl, Ali Ghasemzadeh, Christopher C. Jackson, Phuoc T. Tran, Vladimir Coric, Michael Lim

    Published in Journal for ImmunoTherapy of Cancer (2016-12-01)
    Get full text
    Article


  13. 13

    Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma by Nirmish Singla, Thomas R. Nirschl, Aleksandar Z. Obradovic, Eugene Shenderov, Kara Lombardo, Xiaopu Liu, Alice Pons, Jelani C. Zarif, Steven P. Rowe, Bruce J. Trock, Hans J. Hammers, Trinity J. Bivalacqua, Phillip M. Pierorazio, Julie S. Deutsch, Tamara L. Lotan, Janis M. Taube, Yasser M. A. Ged, Michael A. Gorin, Mohamad E. Allaf, Charles G. Drake

    Published in Scientific Reports (2024-01-01)
    Get full text
    Article


  14. 14

    Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce by Mario Sznol, Roberta Zappasodi, Margaret K. Callahan, Dung T. Le, Robert L. Ferris, James L. Gulley, Charles G. Drake, Ryan J. Sullivan, Elad Sharon, Hussein A. Tawbi, Harriet M. Kluger, Janis M. Taube, Shilpa Gupta, Suzanne L. Topalian, Edward Cha, Michael A. Postow, Vassiliki A. Papadimitrakopoulou, Maria L. Ascierto, Michaela Bowden, Helen X. Chen, David M. Feltquate, Rachel W. Humphrey, Theresa M. LaVallee, Vanessa M. Hubbard-Lucey, Eric H. Rubin

    Published in Journal for ImmunoTherapy of Cancer (2020-05-01)
    Get full text
    Article


  15. 15

    Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 by James L Gulley, Julie R Brahmer, Pedro J Romero, Francesco M Marincola, Charles G Drake, Stefani Spranger, Lisa H Butterfield, Douglas G McNeel, Alessandra Cesano, Thomas F Gajewski, Howard L Kaufman, Bernard A Fox, Leisha A Emens, Mario Sznol, Tanja D de Gruijl, Daniel S Chen, Patrick Hwu, Paolo Antonio Ascierto, Walter J Urba, Jon M Wigginton, Robert O Dillman, Michael B Atkins, Kim A Margolin, Paul M Sondel, Michael T Lotze, Ana Carrizosa Anderson, Ernest C Borden, David Kaufman, Michael J Mastrangelo, Marcela V Maus, David R Parkinson, George J Weiner, Jeffrey S Weber, F Stephen Hodi Jr

    Published in Journal for ImmunoTherapy of Cancer (2020-05-01)
    Get full text
    Article


Search Tools: